Stocksigma LogoStocksigma Logo

Balaxi Pharmaceuticals Reports Strong Q2 Results, Secures WHO-GMP Certification, and Announces Leadership

Balaxi Pharmaceuticals reported consolidated revenue from operations of ₹8,137.23 lakhs for Q2 ended 30th Sep'26, up 44.85% YoY from ₹5,617.53 lakhs

Balaxi Pharmaceuticals Reports Strong Q2 Results, Secures WHO-GMP Certification, and Announces Leadership

Balaxi Pharmaceuticals Ltd · Outcome · 12 Nov 2026, 7:33 pm

Balaxi Pharmaceuticals Reports Strong Q2 Results, Secures WHO-GMP Certification, and Announces Leadership Update Balaxi Pharmaceuticals reported consolidated revenue from operations of ₹8,137.23 lakhs for Q2 ended 30th Sep'26, up 44.85% YoY from ₹5,617.53 lakhs. Net profit rose to ₹115.02 lakhs from ₹20.90 lakhs YoY. The company received WHO-GMP certification from CDSCO for its Jadcherla formulation facility, where commercial production is scaling up for Angola and Dominican Republic markets with 22 products manufactured and approvals reaching 34 products. Additionally, Pranav Maheshwari was redesignated as President – Business and Corporate Strategy, effective 12th Nov'26.

Original exchange filing (PDF)

More announcements from Balaxi Pharmaceuticals Ltd

All Balaxi Pharmaceuticals Ltd announcements